Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore

Adam R. Blanden, Xin Yu, Aaron J. Wolfe, John A. Gilleran, David J. Augeri, Ryan S. O'Dell, Eric C. Olson, S. David Kimball, Thomas J. Emge, Liviu Movileanu, Darren R. Carpizo, Stewart N. Loh

Research output: Research - peer-reviewArticle

  • 14 Citations

Abstract

p53 is a Zn2+-dependent tumor suppressor inactivated in >50% of human cancers. The most common mutation, R175H, inactivates p53 by reducing its affinity for the essential zinc ion, leaving the mutant protein unable to bind the metal in the low [Zn2+]free environment of the cell. The exploratory cancer drug zinc metallochaperone-1 (ZMC1) was previously demonstrated to reactivate this and other Zn2+-binding mutants by binding Zn2+ and buffering it to a level such that Zn2+ can repopulate the defective binding site, but how it accomplishes this in the context of living cells and organisms is unclear. In this study, we demonstrated that ZMC1 increases intracellular [Zn2+]free by functioning as a Zn2+ ionophore, binding Zn2+ in the extracellular environment, diffusing across the plasma membrane, and releasing it intracellularly. It raises intracellular [Zn2+]free in cancer (TOV112D) and noncancer human embryonic kidney cell line 293 to 15.8 and 18.1 nM, respectively, with half-times of 2-3 minutes. These [Zn2+]free levels are predicted to result in ∼90% saturation of p53-R175H, thus accounting for its observed reactivation. This mechanism is supported by the X-ray crystal structure of the [Zn(ZMC1)2] complex, which demonstrates structural and chemical features consistent with those of known metal ionophores. These findings provide a physical mechanism linking zinc metallochaperone-1 in both in vitro and in vivo activities and define the remaining critical parameter necessary for developing synthetic metallochaperones for clinical use.

LanguageEnglish (US)
Pages825-831
Number of pages7
JournalMolecular Pharmacology
Volume87
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Metallochaperones
Ionophores
Zinc
Neoplasms
Metals
HEK293 Cells
Mutant Proteins
Binding Sites
Cell Membrane
X-Rays
Ions
Mutation
Pharmaceutical Preparations
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Blanden, A. R., Yu, X., Wolfe, A. J., Gilleran, J. A., Augeri, D. J., O'Dell, R. S., ... Loh, S. N. (2015). Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. Molecular Pharmacology, 87(5), 825-831. DOI: 10.1124/mol.114.097550

Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. / Blanden, Adam R.; Yu, Xin; Wolfe, Aaron J.; Gilleran, John A.; Augeri, David J.; O'Dell, Ryan S.; Olson, Eric C.; Kimball, S. David; Emge, Thomas J.; Movileanu, Liviu; Carpizo, Darren R.; Loh, Stewart N.

In: Molecular Pharmacology, Vol. 87, No. 5, 01.05.2015, p. 825-831.

Research output: Research - peer-reviewArticle

Blanden, AR, Yu, X, Wolfe, AJ, Gilleran, JA, Augeri, DJ, O'Dell, RS, Olson, EC, Kimball, SD, Emge, TJ, Movileanu, L, Carpizo, DR & Loh, SN 2015, 'Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore' Molecular Pharmacology, vol 87, no. 5, pp. 825-831. DOI: 10.1124/mol.114.097550
Blanden AR, Yu X, Wolfe AJ, Gilleran JA, Augeri DJ, O'Dell RS et al. Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. Molecular Pharmacology. 2015 May 1;87(5):825-831. Available from, DOI: 10.1124/mol.114.097550
Blanden, Adam R. ; Yu, Xin ; Wolfe, Aaron J. ; Gilleran, John A. ; Augeri, David J. ; O'Dell, Ryan S. ; Olson, Eric C. ; Kimball, S. David ; Emge, Thomas J. ; Movileanu, Liviu ; Carpizo, Darren R. ; Loh, Stewart N./ Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. In: Molecular Pharmacology. 2015 ; Vol. 87, No. 5. pp. 825-831
@article{850c3fca8c804ea9b0ed9c7ec8dc3084,
title = "Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore",
abstract = "p53 is a Zn2+-dependent tumor suppressor inactivated in >50% of human cancers. The most common mutation, R175H, inactivates p53 by reducing its affinity for the essential zinc ion, leaving the mutant protein unable to bind the metal in the low [Zn2+]free environment of the cell. The exploratory cancer drug zinc metallochaperone-1 (ZMC1) was previously demonstrated to reactivate this and other Zn2+-binding mutants by binding Zn2+ and buffering it to a level such that Zn2+ can repopulate the defective binding site, but how it accomplishes this in the context of living cells and organisms is unclear. In this study, we demonstrated that ZMC1 increases intracellular [Zn2+]free by functioning as a Zn2+ ionophore, binding Zn2+ in the extracellular environment, diffusing across the plasma membrane, and releasing it intracellularly. It raises intracellular [Zn2+]free in cancer (TOV112D) and noncancer human embryonic kidney cell line 293 to 15.8 and 18.1 nM, respectively, with half-times of 2-3 minutes. These [Zn2+]free levels are predicted to result in ∼90% saturation of p53-R175H, thus accounting for its observed reactivation. This mechanism is supported by the X-ray crystal structure of the [Zn(ZMC1)2] complex, which demonstrates structural and chemical features consistent with those of known metal ionophores. These findings provide a physical mechanism linking zinc metallochaperone-1 in both in vitro and in vivo activities and define the remaining critical parameter necessary for developing synthetic metallochaperones for clinical use.",
author = "Blanden, {Adam R.} and Xin Yu and Wolfe, {Aaron J.} and Gilleran, {John A.} and Augeri, {David J.} and O'Dell, {Ryan S.} and Olson, {Eric C.} and Kimball, {S. David} and Emge, {Thomas J.} and Liviu Movileanu and Carpizo, {Darren R.} and Loh, {Stewart N.}",
year = "2015",
month = "5",
doi = "10.1124/mol.114.097550",
volume = "87",
pages = "825--831",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore

AU - Blanden,Adam R.

AU - Yu,Xin

AU - Wolfe,Aaron J.

AU - Gilleran,John A.

AU - Augeri,David J.

AU - O'Dell,Ryan S.

AU - Olson,Eric C.

AU - Kimball,S. David

AU - Emge,Thomas J.

AU - Movileanu,Liviu

AU - Carpizo,Darren R.

AU - Loh,Stewart N.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - p53 is a Zn2+-dependent tumor suppressor inactivated in >50% of human cancers. The most common mutation, R175H, inactivates p53 by reducing its affinity for the essential zinc ion, leaving the mutant protein unable to bind the metal in the low [Zn2+]free environment of the cell. The exploratory cancer drug zinc metallochaperone-1 (ZMC1) was previously demonstrated to reactivate this and other Zn2+-binding mutants by binding Zn2+ and buffering it to a level such that Zn2+ can repopulate the defective binding site, but how it accomplishes this in the context of living cells and organisms is unclear. In this study, we demonstrated that ZMC1 increases intracellular [Zn2+]free by functioning as a Zn2+ ionophore, binding Zn2+ in the extracellular environment, diffusing across the plasma membrane, and releasing it intracellularly. It raises intracellular [Zn2+]free in cancer (TOV112D) and noncancer human embryonic kidney cell line 293 to 15.8 and 18.1 nM, respectively, with half-times of 2-3 minutes. These [Zn2+]free levels are predicted to result in ∼90% saturation of p53-R175H, thus accounting for its observed reactivation. This mechanism is supported by the X-ray crystal structure of the [Zn(ZMC1)2] complex, which demonstrates structural and chemical features consistent with those of known metal ionophores. These findings provide a physical mechanism linking zinc metallochaperone-1 in both in vitro and in vivo activities and define the remaining critical parameter necessary for developing synthetic metallochaperones for clinical use.

AB - p53 is a Zn2+-dependent tumor suppressor inactivated in >50% of human cancers. The most common mutation, R175H, inactivates p53 by reducing its affinity for the essential zinc ion, leaving the mutant protein unable to bind the metal in the low [Zn2+]free environment of the cell. The exploratory cancer drug zinc metallochaperone-1 (ZMC1) was previously demonstrated to reactivate this and other Zn2+-binding mutants by binding Zn2+ and buffering it to a level such that Zn2+ can repopulate the defective binding site, but how it accomplishes this in the context of living cells and organisms is unclear. In this study, we demonstrated that ZMC1 increases intracellular [Zn2+]free by functioning as a Zn2+ ionophore, binding Zn2+ in the extracellular environment, diffusing across the plasma membrane, and releasing it intracellularly. It raises intracellular [Zn2+]free in cancer (TOV112D) and noncancer human embryonic kidney cell line 293 to 15.8 and 18.1 nM, respectively, with half-times of 2-3 minutes. These [Zn2+]free levels are predicted to result in ∼90% saturation of p53-R175H, thus accounting for its observed reactivation. This mechanism is supported by the X-ray crystal structure of the [Zn(ZMC1)2] complex, which demonstrates structural and chemical features consistent with those of known metal ionophores. These findings provide a physical mechanism linking zinc metallochaperone-1 in both in vitro and in vivo activities and define the remaining critical parameter necessary for developing synthetic metallochaperones for clinical use.

UR - http://www.scopus.com/inward/record.url?scp=84939815338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939815338&partnerID=8YFLogxK

U2 - 10.1124/mol.114.097550

DO - 10.1124/mol.114.097550

M3 - Article

VL - 87

SP - 825

EP - 831

JO - Molecular Pharmacology

T2 - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -